The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress

Myeloproliferative Neoplasms MORE >>

Robyn M. Scherber, MD, MPH, discusses the prevalence of ruxolitinib failure and how it can be managed in patients with MF. She also highlights combinations and other treatment regimens currently under investigation for this patient population.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.